[{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Antibody","year":"2024","type":"Acquisition","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Apeiron Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Apeiron Biologics \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Apeiron Biologics \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"Recordati","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eusa Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eusa Pharma \/ Recordati","highestDevelopmentStatusID":"15","companyTruncated":"Eusa Pharma \/ Recordati"},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eusa Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eusa Pharma \/ BeiGene","highestDevelopmentStatusID":"15","companyTruncated":"Eusa Pharma \/ BeiGene"},{"orgOrder":0,"company":"St. Jude Children","sponsor":"Renaissance Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase II","graph3":"St. Jude Children","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"St. Jude Children \/ Renaissance Pharma","highestDevelopmentStatusID":"8","companyTruncated":"St. Jude Children \/ Renaissance Pharma"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"United Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"United Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Essential Pharma","sponsor":"AGC Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Dinutuximab","moa":"||Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase II","graph3":"Essential Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Essential Pharma \/ AGC Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Essential Pharma \/ AGC Biologics"}]